Tampilkan postingan dengan label Kaiser Health News. Tampilkan semua postingan
Tampilkan postingan dengan label Kaiser Health News. Tampilkan semua postingan

Jumat, 22 September 2017

Why are exchange premiums rising so fast?



Today's Managing Health Care Costs Number is 17%
 

Kaiser Family Foundation and the Health Education Research Trust release a comprehensive review of employer sponsored health insurance each September - and that report dropped this week.   One of the takeaways is that employer sponsored health insurance is increasing in cost at a rate dramatically less than the Affordable Care Act exchanges.  This was picked up by Kaiser Health News (Phil Galewitz briefly quotes me) and by the New York Times.  The graphic above shows a 17% gap between the rate of premium increase for employer sponsored plans compared to individually-purchased exchange plans. 

Employers are making some important efforts to improve the cost effectiveness of care.  This includes narrow high performance networks, earlier intervention with metabolic syndrome, and centers of excellence.  But there are other big reasons why the costs of employer sponsored insurance, especially large self-insured companies, are more stable than the costs of the exchanges.

  1. Risk selection
    Employees tend to be healthier than those purchasing insurance on the exchanges.   They often leave their employment if they get exceptionally sick.  But more importantly, an employer offers coverage to all of her employees - and the 10% with the highest risk all take up the offer, but they are "diluted" by the fact that 70 or so percent of all employees accept insurance- so members in the top decile of risk only represent 1/7 of the total population.  Insurance takeup at smaller employers is lower - often closer to 30% - so those in the top decile of risk could represent 1/3 of the insured population.    It's even worse in the individual market - where the top decile of risk could represent as much as a majority of all insured.   Individual markets are especially susceptible to "death spirals," where the increasing cost of insurance chases away all potential low-risk subscribers.  

    The individual mandate should help keep younger and healthier people in the risk pool - but the Trump Administration has signaled that it is loath to enforce this. 

    The Trump Administration also cut 90% of the advertising budget and has
    forced firing of most of the health care navigators across the states by not approving budgets.   Sick people are likely to find their way to the exchanges - while we are not making it easy for those without a large illness burden to do the same
     
  2. Government Interference
    The
    Congressional Budget Office notes that rate increases of 15% on the ACA exchange markets could be related to the uncertainty about whether the Cost Sharing Reduction (CSR) payments will continue through the next calendar year.  The Trump Administration has offered mixed messages on this - and insurers have to build rates as if they will not get these payments at some point in the future.

    CMS has also
    used ACA funds to produce material discouraging ACA enrollment - which can lead to market confusion and worsening risk profile of those who do enroll. 
     
We don't adequately appreciate that the Affordable Care Act has actually helped lower the cost of employer sponsored health insurance, too.    The ACA included decreases in the rate of increase of Medicare fee schedules.   Most commercial health plans pay fee for service for care delivered - and these fee schedules are almost all based on Medicare fee schedules.  As the Medicare fee schedule stays closer to flat - it's easier to avoid raising the commercial fee schedules as well. 

Kamis, 06 Juli 2017

TrumpCare: Defective insurance plans to fleece policyholders




Today's Managing Health Care Costs Number is  49.5%


As Kim Jung Un fires ballistic missiles into the waters off Japan and Donald Trump encourages the right wing in Poland, the Senate continues to work under the cover of heavy secrecy on a bill to strip health care from tens of millions. 

But that's not enough.   In the name of free markets, Ted Cruz has suggested that insurance companies should be allowed to sell insurance plans that do not comply with pre-existing condition prohibitions or offer all ACA-required essential benefits  - as long as in each state they offer at least one plan that does comply with ACA requirements. 

Here's how this would work.   Insurers would offer one plan that complied with the Affordable Care Act.  This plan would  cover maternity (just think!), mental health services, ambulance rides, prescription drugs, and emergency rooms. (All of these requirements would be waived in the non-compliant plans).   The plan would be available for the same price to all comers, whether they were healthy or had preexisting illnesses.  The plan would be attractive to those at high risk - so it would have to have a high price.  It would also likely be saddled with the largest allowable deductibles and coinsurance - to discourage utilization and to keep the premium from being even higher.   

This plan is the definition of a "death spiral."  Insurers would offer compliant plans to gain the right to offer the less inclusive plans, which would be priced to sell.   Risk for having babies or taking expensive medicines would be transferred to individuals - as healthy members would no longer be subsidizing the sick.    Those with preexisting illnesses could choose between affording their housing or their health insurance. 

What would noncompliant insurance look like for those at low risk who could make it through the underwriting process to gain eligibility?  For starters, it would be cheap!   Five percent of the population represents49.5% of all medical costs - so you could design an insurance plan for 40% less if you could exclude those expensive patients - and still make a whopping profit.  But Mitch McConnell will focus on the lower prices, not he value of the available plans.     

However that noncompliant plan would be a bum deal.   It could be a "mini-med" plan which had a cap of a few thousand dollars - enough for an emergency room visit.  (These were banned by the ACA - but would be revived under Trumpcare).   It would exclude specialty medications which often cost $100,000 a year, and would not cover mental health services.  It would be designed to be unattractive to those with real needs -because that's how to make such a plan profitable.  Do you need maternity care?  Then buy a rider priced at the cost of delivery!


These plans would have very low "medical loss ratios."   Under the ACA, insurers must issue refunds if their administrative costs exceed 15-20%.   Those rebates would go away - and insurance company profitability would soar.   That's why health plans are ambivalent about TrumpCare.  They hate going back to offering plans designed to exclude coverage for the sick - but those profits are mighty attractive.

Even worse, the bottom 50% of the population represents under 3% of total costs.   Imagine how cheap the health plan catering to just the healthiest half of the population could be - while leaving room for healthy profits. 
  
We don't allow automakers to sell cars without bumpers.  We don't allow furniture makers to sell baby cribs that have risk of finger amputation or decapitation.  The government has a role in promoting public safety -and this role includes structuring markets to prevent the sale of defective or dangerous goods.  

There's no reason to allow the resurrection of insurance plans that fleece  policyholders and leave sick people with no coverage.  The Senate should reject this terrible idea.

Kamis, 22 Juni 2017

Lowering drug prices by raising drug prices.

Today's Managing Health Care Costs Number is 1/6


Kaiser Health News and the New York Times have reported on the four page Trump executive order to decrease drug prices.    He's going for irony -- he will decrease drug prices by raising them.

The recommendation comes from Trump's Drug Pricing and Innovation Workgroup, which is chock full of pharma industry executives.  As Kaiser Health News reports:

To solve the crisis of high drug prices, the group discussed strengthening the monopoly rights of pharmaceuticals overseas, ending discounts for low-income hospitals and accelerating drug approvals by the Food and Drug Administration. 

So - the administration thinks that if pharma companies are able to earn more dollars in India or Brazil they will lower their prices in the US?    That's simply not how pricing works!  The pharmaceutical companies have been plenty profitable overall and that has not led to any relief of steady price inflation.  Drug companies charge what the market will pay - and allowing them higher profits in one arena doesn't simply lower prices somewhere else. New oncology and specialty drugs routinely cost over $100,000 a year, and price increases on existing medications continue to outpace inflation.

The Administration would also decrease 340b discounts to hospitals and providers who serve low income communities.   Exactly how that would help drug prices?   It would increase pharmaceutical industry profitability allowing the drug companies to lower their prices overall.   Does anyone really believe that?

There's more.   The executive order could allow pharmaceutical companies to provide marketing material to insurers and pharmacy benefit managers before FDA approval, and "use less rigorous clinical trial standards to speed drug approvals."  I can see how this could decrease value (encouraging the use of new expensive drugs with little or no benefit beyond older established drugs).  But I can't see how this will decrease cost!

The FDA released a blog post promising action to prevent brand name legal tactics that delay introduction of generic medications.  That is one element of the Trump plan that could lead to some price relief.   However, the problem we face is the cost of brand name drugs.  We should push to get faster approval for generics, and we should allow importation of generics from other developed countries when we face shortages in the US. 

But we need action to decrease the price of new medications.   There are potential answers out there:
  • Medicare could negotiate prices (prohibited by the Medicare Part D enabling legislation).
  • The FDA could consider cost in drug approval (prohibited by current rules). 
  • The National Institutes of Health could "march in" and retake patents for drugs which are priced too high
  • We could implement an excise tax on excessive prices.  We could enable payments for expensive effective medications over the period of benefit rather than "up front."  

Here are a set of recommendations from Consumer Reports

But the Trump Administration drug plan is the answer to the pharmaceutical industry's wish list. It will raise overall drug costs abroad through actions to protect patents, and it will raise overall drug costs here by cracking down on 340b discounts. 

Kamis, 18 Mei 2017

FDA regs save Medicare $80 billion

.
Today's Managing Health Care Costs Number is $80 billion



The US government dodged an $80 billion dollar bullet by requiring extensive testing before approval of Solanezumab, a new Alzheimer's Disease medication, according to new research in the New England Journal of Medicine. Eli Lilly did two human studies that found the drug no better than placebo, but subgroup analysis suggested that it might be helpful in those with especially early disease.   A trial to examine this, however, also showed no effect of the drug.


That's bad news for Eli Lilly's shareholders -but it's good news for patients who won't be given  (1) false hope (2) inevitable side effects and complications and (3) giant bills.  And it's especially good news for Medicare.  The researchers estimate that the cost of this drug to Medicare alone, were it approved, would have likely been about $80 billion over a four year period.  This good regulatory outcome was only possible because the FDA takes its job seriously and looks to approve only drugs with a credible chance of improving patient health.


The FDA mission would change, though, if it followed the recommendations of a group of scientists and advocates writing for US Against Alzheimers.  This organization (at least partially funded by the pharmaceutical industry) advocates that "the FDA should clarify for the field that a clinically meaningful benefit on a single primary endpoint of cognition or function is a sufficient basis for a New Drug Application filing." In other words, no need for new drugs to improve both cognition and function - improving one alone is enough.   There is already substantial controversy about the current group of Alzheimers drugs approved under the current approach.  These drugs consistently show modest improvement on psychometric testing which some critics feel is not clinically significant.


The current administration is clearly aiming to dramatically decrease regulation.  But easing the rigor of drug approval, in a time when new drugs are always priced at very high prices, has the potential to dramatically increase the cost of health care.   This is especially problematic in the US with direct to consumer advertising, where research shows that marketing



It's most important in the US that the FDA hold firm and not approve drugs that are of no marginal benefit, as once approved marketing (as opposed to research) can drive drugs to be blockbusters.

Jumat, 21 April 2017

 Could we have a death panel for TrumpCare?

Could we have a death panel for TrumpCare?


Today’s Managing Health Care Costs Number is 217


Dylan Scott of Vox calls this Vampire TrumpCare – because attempts to revive the reviled American Health Care Act continue to proliferate – and the bad ideas embodied in this bill just can’t seem to be killed.

1)      The Freedom Caucus of hard-line right-wing Republicans and the Tuesday Group of self-styled moderate Republicans have been debating options to allow states to opt out of the insurance reforms of the ACA as long as they have high risk plans where disadvantaged sick people can seek refuge.   But these high risk plans are always under-funded – so many will be unable to afford the premiums.   Bad idea.

2)     Ted Cruz inveighs against the unaffordable mandates and essential benefits.   But the most controversial – free contraception – actually lowers the cost of health care.  And do we really want health plans that don’t cover maternity care, or mental health. Yup – I’m a guy in my 50s and I won’t personally be using a maternity benefit again.   But I don’t want young moms and families bankrupted by the cost of delivering a baby!  We already have the least friendly environment for young families (no mandatory maternity and paternity leave, for instance).   Do we want to make this worse?  Julie Rovner has a nice summary today in Kaiser Health News showing that the cost of these mandatory benefits is not what’s breaking the bank. Rovner also points out that doing away with standardization of insurance will make it impossible to have risk sharing for high cost members across plans.

3)      States should have choice.    Sounds good in theory – and I don’t want to have Oklahoma deciding health care policy in Massachusetts.  The New York Times has a review of how two states with Republican governors, New Mexico and Oklahoma, had vastly different approaches to Medicaid expansion and exchanges.  In New Mexico the uninsured rate plummeted, there is brisk competition of insurers on the exchanges, and premium increases have been modest.  In Oklahoma – Obamacare is a disaster.  The Supreme Court designed a great natural experiment about what happens when states have the ability to decide not to implement federal health care policy.  Just look at the disparity among states in Medicaid expansion to see how well that worked!
 
4)      All Republican repeal plans erase the individual mandate.  Fine – no one wants to be told what to do.  But getting the healthy to purchase insurance is critical to having sustainable insurance markets.  Insurers won’t sell insurance at reasonable prices if people only purchase that insurance when they are already sick, much as you can’t purchase home insurance when  your house is burning down.  Many dislike the individual mandate philosophically – but have offered no great alternative. Regina Herzlinger, a conservative, pro-market Harvard Business School professor, has a review in JAMA of how Switzerland, Germany and Singapore achieve universal coverage without turning to a single payer . The answer in two words: Individual Mandate. The answer in a paragraph:

Switzerland, Singapore, and Germany have achieved universal coverage and made insurance affordable even for their citizens with highest health care costs by instituting an individual mandate. One major difference, however, is that unlik   e the ACA, the mandates instituted by these countries are reinforced with effective penalties for nonparticipation, thus ensuring that lower-cost enrollees—generally healthier individuals—balance out the costs of the others who require more medical resources.

Trump has set another deadline for voting on TrumpCare: Wednesday 4/27.   The bill continues to be a collection of bad ideas that have already been disproven in the market.   Sarah Kliff points out that the barriers to passing this poorly designed legislation are Yuge.  They need 217 votes – let’s hope they continue to fall short. 

Rabu, 05 April 2017

Prices matter


Today’s Managing Health Care Costs Number is $356,884.42


There are two articles in the news this week that show that price matters. (Not Tom Price, the HHS Secretary, who also matters!).

Elisabeth Rosenthal, long-time NY Times reporter who is now the editor in chief of Kaiser Health News, has an article in the NY Time Magazine “Those Indecipherable Health Care Bills: They’re One Reason Health Care Costs So Much.”  

Wanda Wickizer awoke from her brain bleed with months of recovery ahead of her. She lost her insurance after her husband died, and found bills including:
·        $356,884.42 from the hospital
·        $50,000 for the air ambulance
·        $78,000 from the medical group for professional services
·        $16,000 from the emergency department
Rosenthal reviews the history of medical coding and the escalating battle between providers – who use codes to upgrade their fees – and insurance companies, which use the same codes to cut fees down.  Left out of this battle altogether are those who have no insurance company to run interference with them.  Even with a team of expert volunteers, Wickizer had a hard time figuring out her inscrutable bills –and had little luck negotiating decreases.

Hospitals often say that their “chargemasters,” which are the “rack rates” or “asking price,” are irrelevant since no one pays them anyway.    

But that’s not true.

Research published in Health Affairs on Monday demonstrates that hospitals which increase their chargemaster by a dollar receive an extra 15 cents in revenue.  So – someone IS paying these rack rates!    The research also shows that when California prohibited billing more than Medicare rates to those without insurance who had incomes under 350% of the federal poverty limit, the actual amount paid by uninsured patients of modest income decreased dramatically.

By the way, the researchers also investigated whether higher chargemasters were associated with better quality.    There was no association.

This is solid evidence that some type of price ceiling could lower the actual cost of medical care in the US – because the price charged does indeed matter


This shows that when chargemasters increased, the uninsured paid much more in California before 2007, and did not subsequently   Source

Rabu, 12 Oktober 2016

How the pharmacy dollar is divided


Today’s Managing Health Care Costs Number is 15.5%


Distribution of Payment for a Drug



Pharmacy costs are escalating rapidly, and we often focus on the brand name pharmaceutical companies.  Many of these companies have rapidly inflated their prices, often on drugs that are close to losing their patent protection, and where any past research investment has long ago been paid off.

Julie Appleby of Kaiser Health News put together an infographic last week that explains how many dollars are siphoned off at each stage of drug distribution, using a hypothetical brand name drug with a “list” wholesale price of $250.   I’ve been noodling with this for a number of days to figure out, in her example, who really makes what money when this prescription is filled?

First of all – on the “sources” side, the employer is paying $182 and the patient is paying $25 – so the total amount spent on the drug  is $207.   The  list price “wholesale acquisition cost, or WAC is $250 and the AWP is $300 (AWP stands for  “average wholesale price,” or as Appleby says “ain’t what’s paid”.)

Now- how is that $207 split up?

The Pharmacy Benefit Manager (likely CVS Caremark, Express Scripts, or Optum Rx) is paid $15.50, the wholesaler is paid $2.50, and the pharmacy is paid $14. This leaves $175 for the pharmaceutical company.   The total amount taken by intermediaries is $32, or 15.5% of the total paid by the employer and the patient.


This isn’t necessarily high – remember that this 15% is not pure profit.  Pharmacies have to keep the lights on, PBMs have to  contract with the pharmaceutical companies and manage claims, and wholesalers have to get the drug to the pharmacy.  We often pay more than 15% of the cost of acquisition of a product to middlemen –whether they are auto dealers or grocery stores.

But as drug prices increase, the absolute amount paid to intermediaries has continued to increase, even while the resource costs expended by each intermediary has not increased at such a rapid clip.  Appleby’s graphic shows us at least one reason why intermediaries are not exactly bummed out at rapid drug price increases.